Pages that link to "Q38842714"
Jump to navigation
Jump to search
The following pages link to Pharmacogenetic Associations of Antipsychotic Drug-Related Weight Gain: A Systematic Review and Meta-analysis (Q38842714):
Displaying 27 items.
- Theranostic Biomarkers for Schizophrenia (Q33624412) (← links)
- TOX and ADIPOQ Gene Polymorphisms Are Associated with Antipsychotic-Induced Weight Gain in Han Chinese (Q37714911) (← links)
- Intrinsic and Antipsychotic Drug-Induced Metabolic Dysfunction in Schizophrenia (Q38626655) (← links)
- Participants' Voices From Within a Healthy Lifestyle Group. (Q38785766) (← links)
- Pharmacogenomics of autism spectrum disorder (Q39154436) (← links)
- Antipsychotic-associated weight gain: management strategies and impact on treatment adherence (Q41546064) (← links)
- Roman high and low avoidance rats differ in their response to chronic olanzapine treatment at the level of body weight regulation, glucose homeostasis, and cortico-mesolimbic gene expression (Q47188807) (← links)
- Impact of histamine receptors H1 and H3 polymorphisms on antipsychotic-induced weight gain (Q47257590) (← links)
- Genetic variants impacting metabolic outcomes among people on clozapine: a systematic review and meta-analysis. (Q47628101) (← links)
- Pharmacogenetics in psychiatry: state of the art (Q49567721) (← links)
- Mechanisms underlying metabolic disturbances associated with psychosis and antipsychotic drug treatment (Q50156396) (← links)
- Recent Progress in Pharmacogenomics of Antipsychotic Drug Response. (Q52626353) (← links)
- Blood-Based Lipidomics Approach to Evaluate Biomarkers Associated With Response to Olanzapine, Risperidone, and Quetiapine Treatment in Schizophrenia Patients. (Q54942497) (← links)
- Predictors and Moderators of Antipsychotic-Related Weight Gain in the Treatment of Early-Onset Schizophrenia Spectrum Disorders Study (Q57164581) (← links)
- Schizophrenia Polygenic Risk Score as a Predictor of Antipsychotic Efficacy in First-Episode Psychosis (Q58609186) (← links)
- Is It Possible to Predict the Future in First-Episode Psychosis? (Q59335564) (← links)
- Second-generation antipsychotics and metabolism alterations: a systematic review of the role of the gut microbiome (Q61943520) (← links)
- Effect of Metformin on Antipsychotic-Induced Metabolic Dysfunction: The Potential Role of Gut-Brain Axis (Q64063469) (← links)
- A simulations approach for meta-analysis of genetic association studies based on additive genetic model (Q88168913) (← links)
- Progress in Genetic Polymorphisms Related to Lipid Disturbances Induced by Atypical Antipsychotic Drugs (Q89964094) (← links)
- A new genetic locus for antipsychotic-induced weight gain: A genome-wide study of first-episode psychosis patients using amisulpride (from the OPTiMiSE cohort) (Q90002693) (← links)
- The role of genetics and genomics in clinical psychiatry (Q90728372) (← links)
- Molecular pathway analysis associates alterations in obesity-related genes and antipsychotic-induced weight gain (Q90752018) (← links)
- The Role of Proopiomelanocortin and α-Melanocyte-Stimulating Hormone in the Metabolic Syndrome in Psychiatric Disorders: A Narrative Mini-Review (Q91669876) (← links)
- Striatal volume and functional connectivity correlate with weight gain in early-phase psychosis (Q91961363) (← links)
- Potential pharmacogenomic targets in bipolar disorder: considerations for current testing and the development of decision support tools to individualize treatment selection (Q97427309) (← links)
- C677T Polymorphism in the MTHFR Gene Is Associated With Risperidone-Induced Weight Gain in Schizophrenia (Q97883161) (← links)